ClinicalTrials.gg

Program

SYHA1813

A development code. Also written as “SYHA1813 oral solution (2.0g:25mg)” and “SYHA1813 oral solution (20ml:200mg)”.

Its studies are mostly in Meningioma, led by Shanghai Runshi Pharmaceutical Technology.

Furthest: phase 3, since May 18, 20264 company-led studies, 3 open or runningNext primary completion: Jan 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Runshi Pharmaceutical Technology43 open or runningphase 3since May 18, 2026Nov 27, 2023Jan 31, 2027phase 2 · NCT06739213
  • Named in cspc pharmaceutical group’s own pipeline as SYHA1813, phase 3, as of Aug 20, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 27, 2023First study: phase 1 study in Healthy ParticipantsFirst studyNCT06157918 · 19 enrolled · China
  2. Nov 8, 2024Phase 2 study in Unresectable Locally Advanced or Metastatic Solid TumorsNCT06682611 · 380 planned
  3. Dec 9, 2024Phase 2 study in RecurrenceNCT06739213 · 56 planned
  4. May 18, 2026Phase 3 study in High Grade MeningiomaPhase 3 reachedNCT07613450 · 136 planned

Ahead

  1. Nov 13, 2026Primary completion: phase 2 study in Unresectable Locally Advanced or Metastatic Solid TumorsNCT06682611
  2. Jan 31, 2027Primary completion: phase 2 study in RecurrenceNCT06739213
  3. Jul 31, 2029Primary completion: phase 3 study in High Grade MeningiomaNCT07613450

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07613450High Grade Meningioma3Not yet recruitingJul 31, 2029136
NCT06739213Recurrence2Not yet recruitingJan 31, 202756
NCT06682611Unresectable Locally Advanced or Metastatic Solid Tumors2Not yet recruitingNov 13, 2026380
NCT06157918Healthy Participants · China1CompletedJan 26, 202419

How it is read

Names in the registry

  • “SYHA1813”, 3 entries
  • “SYHA1813 oral solution (2.0g:25mg)”, 1 entry
  • “SYHA1813 oral solution (20ml:200mg)”, 1 entry

Codes read as this program: SYHA1813.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.